Treatment Name

RPI-78M

FDA Status

Phase II

Company

ReceptoPharm, Inc.

Official Description

RPI-78M is being developed for the treatment of neurological disorders including Multiple Sclerosis (MS) and Adrenomyeloneuropathy (AMN).

Expanded Description

RPI-78M is being developed for the treatment of multiple sclerosis (MS). Other neurological disorders that may be served by RPI-78M include myasthenia gravis (MG), Adrenomyeloneuropathy (AMN) and amyotrophic lateral sclerosis (ALS).

RPI-78M possesses several desirable properties as a drug:

- It lacks measurable toxicity but are still capable of attaching to and affecting the target site on the nerve cells. This means that patients cannot overdose.

- It displays no serious adverse side effects following years of investigations in humans and animals.

- It is extremely stable and resistant to heat, which gives the drugs a long shelf life. The drugs’ stability has been determined to be over 4 years at room temperature. This is extremely unusual for a biologic drug.

- It is easy to administer. RPI-78M can be administered orally-a first for a biologic MS drug. This will present MS patients with additional quality of life benefits by eliminating the requirement for routine injections.

Back to community details